Specialty drug market success requires patient-focused and therapy-specific channel and services strategies
Ron Krawczyk, Jennifer Hamilton, Jason Bogroff, Blue Fin Group
Advertisement
Articles by Ron Krawczyk, Jennifer Hamilton, Jason Bogroff, Blue Fin Group
Advertisement
Latest Updated Articles
- Specialty drugs are generating a new paradigm: Commercial Innovation
Published: November 29th 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Mark Cuban Confirms Cost Plus Drugs Partnership
2
Why Rising Complexity and R&D Costs Are Fueling Specialty Drug Spending
3
Pharma Pulse: Telehealth Medication Abortion Requests Surge, FDA Expedites Tzield Review, and New Biopharma Air Network Launches
4
Pharma Pulse: MJH Life Sciences Expands into Health Systems, Novo Nordisk Board Shakeup Moves Markets, and Mark Cuban Grows Cost Plus Drugs Network
5
